Inhibition of human initiator caspase 8 and effector caspase 3 by cross-class inhibitory bovSERPINA3-1 and A3-3  by Herrera-Mendez, Carlos H. et al.
FEBS Letters 583 (2009) 2743–2748journal homepage: www.FEBSLetters .orgInhibition of human initiator caspase 8 and effector caspase 3 by cross-class
inhibitory bovSERPINA3-1 and A3-3
Carlos H. Herrera-Mendez d,1, Samira Becila c,1, Xavier Blanchet b,1, Patrick Pelissier b, Didier Delourme b,
Gerald Coulis a, Miguel A. Sentandreu e, Abdelghani Boudjellal c, Laure Bremaud b, Ahmed Ouali a,*
aUR370, QuaPA, INRA de Clermont Ferrand – Theix, 63122 Saint Genes Champanelle, France
bUGMA, UMR 1061, INRA-Université Limoges, 123, Avenue Albert Thomas, 87060 Limoges Cedex, France
c INATAA, Université de Constantine, Route de Aïn El Bey, 25000 Constantine, Algeria
dUNESS, Universidad de Guanajuato, Privada de Arteaga S/N, 38900 Salvatierra, Guanajuato, Mexico
eDepartment of Food Science, C.S.I.C., Apt. 73, 46100 Burjassot, Valencia, Spain
a r t i c l e i n f o a b s t r a c tArticle history:
Received 8 June 2009
Revised 21 July 2009
Accepted 30 July 2009
Available online 7 August 2009
Edited by Gianni Cesareni
Keywords:
Caspase
bovSERPINA3
Serpin
Inhibitor
Bovine muscle0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.07.055
Abbreviations: CrmA, cytokine response modiﬁer
ﬂuoromethylketone; kass, association rate constant;
arylamide; PAGE, polyacrylamide gel electrophoresis;
reactive centre loop; SDS, sodium dodecyl sulfate; Z,
* Corresponding author. Fax: +33 4 73 62 42 68.
E-mail address: ouali@clermont.inra.fr (A. Ouali).
1 These three authors contributed similarly to the prSerpins are a superfamily of structurally conserved proteins. Inhibitory serpins use a suicide sub-
strate-like mechanism. Some are able to inhibit cysteine proteases in cross-class inhibition. Here,
we demonstrate for the ﬁrst time the strong inhibition of initiator and effector caspases 3 and 8
by two puriﬁed bovine SERPINA3s. SERPINA 3-1 (uniprotkb:Q9TTE1) binds tighly to human CASP3
(uniprotkb:P42574) and CASP8 (uniprotkb:Q14790) with kass of 4.2  105 and 1.4  106 M1 s1,
respectively. A wholly similar inhibition of human CASP3 and CASP8 by SERPINA3-3 (uni-
protkb:Q3ZEJ6) was also observed with kass of 1.5  105 and 2.7  106 M1 s1, respectively and
form SDS-stable complexes with both caspases. By site-directed mutagenesis of bovSERPINA3-3,
we identiﬁed Asp371 as the potential P1 residue for caspases. The ability of other members of this
family to inhibit trypsin and caspases was analysed and discussed.
Structured summary:
MINT-7234656: CASP8 (uniprotkb:Q14790) and SERPINA3-1 (uniprotkb:Q9TTE1) bind (MI:0407) by bio-
chemical (MI:0401)
MINT-7234634: SERPINA3-3 (uniprotkb:Q3ZEJ6) and CASP3 (uniprotkb:P42574) bind (MI:0407) by bio-
chemical (MI:0401)
MINT-7234663: CASP8 (uniprotkb:Q14790) and SERPINA3-3 (uniprotkb:Q3ZEJ6) bind (MI:0407) by bio-
chemical (MI:0401)
MINT-7234625: SERPINA3-1 (uniprotkb:Q9TTE1) and CASP3 (uniprotkb:P42574) bind (MI:0407) by bio-
chemical (MI:0401)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Most are inhibitory, which employ a unique suicide mechanismSerpins, a large family of structurally related proteins, are
widely distributed among eukaryotes and in some bacteria and
viruses. They are involved in many highly regulated physiological
processes such as blood coagulation, ﬁbrinolysis, cell migration
and inﬂammation [1,2] and serpin dysfunctions can have severe
pathological consequences [3].chemical Societies. Published by E
A; DTT, dithiothreitol; FMC,
NHMec, aminomethyl coum-
PI9, protease inhibitor 9; RCL,
benzyloxycarbony
esent work.for inactivation of their target proteases. In the well understood
case of serine proteases, after the formation of the non-covalent
Michaelis complex and the subsequent cleavage of the peptide
bond, the loop will insert into the core of the protein giving rise
to an additional beta-sheet and transporting in the mean time
the bound enzyme with it to the distal pole of the serpin. The com-
pressed peptidase is distorted and this distortion is responsible for
its inactivation and its inability to complete the peptide bond
hydrolysis [4]. However some of them are able to inactivate both
serine and cysteine proteases; this property is termed cross-class
inhibition. We thus can mention the inhibition of prohormone
thiol protease by a1-antichymotrypsin [5,6] or of cathepsin L and
papain by Endopin 2 [7] but this list is not exhaustive. To date,
few serpins have been reported to inhibit caspases. The ﬁrst tolsevier B.V. All rights reserved.
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to inhibit the cytotoxic serine protease granzyme B but also a ser-
ies of caspases [8,9]. Human endogenous serpin PI9, a poor inhib-
itor of caspases 1, 4 and 8 [10], became more efﬁcient against
caspase after mutation of its P1 residue from glutamate to aspar-
tate and able to block Fas-mediated apoptosis [11].
Recently, we related the complete organization of the bovine
SERPINA3 cluster [12]. These serpins were found to be essentially
intracellular and widely distributed in bovine tissues and cells
[13]. Two members of this family, bovSERPINA3-1 and bovSERPIN-
A3-3, previously named Endopin 1A and Endopin 1B, respectively,
were puriﬁed and shown to inhibit strongly elastase and trypsin
but neither papainnor cathepsins B and L [13,14]. Thepresent report
demonstrates, for the ﬁrst time, an anti-caspase activity ofmamma-
lian SERPINA3s.We provide evidence that bovSERPINA3-1 and bov-
SERPINA3-3 are able to strongly inhibit initiator caspase 8 and
effector caspase 3. They formSDS-stable complexeswith their target
enzymes with association rate constants ranging from 1.5  105 to
2.7  106 M1 s1. Attempt to identify the P1 residue, Asp37 (residue
371 in the mature protein) residue in the reactive centre loop (RCL)
was mutated to Ala37 in bovSERPINA3-3 and the mutated form still
inhibited trypsin but no longer caspase 3 or 8. This ﬁndingwas com-
forted by preliminary analysis of the N-terminal sequence of the
peptide generated from the serpin, after covalent complex forma-
tion. RCL sequences of all bovSERPINA3s’ members were aligned
and compared and their potential ability to inhibit caspases dis-
cussed. It was concluded that bovSERPINA3-1 and bovSERPINA3-3
might be signiﬁcantly relevant in situ inhibitors of caspases and con-
sequently of programmed cell death. Furthermore, such function
might be shared by other members of this family.
2. Materials and methods
2.1. Titration of enzymes and inhibitors
Enzyme and inhibitor titration was performed as previously de-
scribed [14]. Speciﬁc irreversible inhibitors Z-Asp-Glu-Val-Asp-
FMCand Z-Val-Glu-Leu-Asp-FMCwere used for titration of caspases
3 and 8, respectively. The activitywas determined by using the ﬂuo-
rescent substrates N-Acetyl-Asp-Glu-Val-Asp-NHMec and Ac-Ile-
Glu-Pro-Asp-NHMec, respectively [15]. Caspase concentrations are
expressed as the number N of active sites titrated by the speciﬁc
inhibitor in nMandnot the amount of active enzymemolecules con-
taining twoactive sites (activeenzyme = N/2). Serpinconcentrations
are expressed as the number of active protein molecules in nM.
Human recombinant caspases 3 and 8 from Sigma were used
throughout the present work. The commercial preparations of
caspases were found to be about 80% active.
2.2. Association rate constants
The association rate constants characterizing capsapses 3 and 8
interaction with bovSERPINA3-1 and A3-3 were determined by the
progress curve method (Ref. [16] and details provided in the Sup-
plementary data).
2.3. SDS–PAGE analysis of EI complexes and protein preparations
One volume of SDS buffer (30 mM Tris–HCl buffer pH 6.8 con-
taining 4% SDS and 1% mercaptoethanol) was added to the protein
samples before heat denaturation for 5 min in a boiling water bath.
Electrophoresis was performed on 12% polyacrylamide slab gels.
2.4. Peptide preparation and N-terminal sequence analysis
An aliquot of the enzyme/inhibitor mixture was diluted with
denaturing buffer (1/1, V/V) (4% SDS, glycerol 20%, Tris 120 mM,pH 6.8, dithiothreitol (DTT) 200 mM, bromophenol blue 0.004%),
heated for 5 min before cooling in ice. Samples were loaded on a
16.5% gel and run for 6 h under a 20 mA current. The gel was trans-
ferred to an Immobilon-PSQ membrane and then stained with Coo-
massie blue. The band was cut off and subjected to N-terminal
sequencing by the Edman method using an Applied Biosystems
477A pulsed liquid sequencer (Perseptive Biosystems, Framing-
ham, MA, USA). Phenylthiohydantoin derivatives were identiﬁed
with an on-line model 120A analyser.
2.5. Expression and puriﬁcation of wild-type and mutant forms of
recombinant bovSERPINA3-3
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jol-
la, CA, USA) was utilized to generate mutant form of bovSERPINA3-
3 that substituted Ala37/ for Asp37 (residue Asp371 in the mature
protein) using 50-GATGCTCTGGGTGGCTTTGAGAACTAC-30 and re-
verse 50-GTAGTTC TCAAAGCCACCCAGAGCATC-30 primers. Wild-
type (WT) and mutant forms were each expressed in Escherichia
coli BL21-RP CodonPlus (DE3)-RP strain (Stratagene) by use of
the pET19b plasmid vector (Novagen, Madison, WI). Proteins were
expressed with an NH2-His tag, which allows afﬁnity puriﬁcation
on a Ni2+ column. Puriﬁcation was performed using Ni-NTA Fast
Start column (QIAGEN, Les Ulis, France) according to the manufac-
turer’s recommendations and then dialysed.
2.6. Protein determination
Protein concentrations were measured by using the Bradford’s
method (Bio-Rad protein assay) with rabbit immunoglobulin as
the standard [17].3. Results and discussion
BovSERPINA3-1 (GenBank: AAY22405), a 70 kDa serpin, and
bovSERPINA3-3 (GenBank: AAY22406), a 75 kDa serpin, were
puriﬁed from bovine skeletal muscle as previously described
[14]. As assessed by sodium dodecyl sulfate (SDS)–polyacryl-
amide gel electrophoresis (PAGE) and silver staining, both ser-
pin preparations are highly pure (Fig. 1a). Both inhibit
strongly elastase and trypsin whereas no activity was detected
against papain and other papain-like proteases (cathepsins B
and L) [13,14]. The fact that none of the serine peptidases
tested and inhibited by the bovSERPINA3s, is expressed in mus-
cle cells led us to search for potential intracellular target en-
zymes including cysteine and serine proteases. Amongst the
large set of proteases tested, caspases were the only one to
be strongly inhibited by both serpins. Within the caspase family
and because they were the most documented caspases in the
ﬁeld of apoptosis development [18,19], the initiator caspase 8
and the effector caspase 3 were selected to study their interac-
tion with bovSERPINA3-1 and A3-3.
3.1. Stoechiometry for caspases inhibition
Amongst the macroscopic parameter deﬁning the effectiveness
of serpins inhibition of particular target protease [20], the ﬁrst one
is the Stoechiometry of Inhibition (SI). To assess the stoechiometry
of interaction, human recombinant caspase 3 and caspase 8 were
titrated with bovSERPINA3-1 and A3-3. Residual activities (Vi/Vo)
were then plotted versus the inhibitor concentration (Fig. 1b and
c). Note that the enzyme concentrations indicated in the ﬁgures
correspond to the number of enzyme active sites titrated with
the speciﬁc synthetic inhibitor, i.e. 2 nM (equivalent to 1 nM of ac-
tive enzyme) and 7 nM (equivalent to 3.5 nM of active enzyme) for
Fig. 1. Homogeneity of the puriﬁed bovSERPINA3-1 and A3-3 and stoechiometry of interaction with caspase 3 and 8. (a) Homogeneity of the serpin preparation as assessed by
SDS–PAGE and silver staining. (b) Stoechiometry of interaction of bovSERPINA3-1 with caspase 3 (1 nM) and caspase 8 (3.5 nM). (c) Stoechiometry of interaction of
bovSERPINA3-3 with caspase 3 (1 nM) and caspase 8 (3.5 nM). In b and c the concentrations indicated are the number of active sites in nM (A. Sites) as determined by titration
with the corresponding speciﬁc inhibitor. The cross point of the linear part of the plot with the x-axis correspond to the amount of inhibitor needed for total inhibition of the
active sites titrated (for details, see Section 3.1).
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ratio are depicted in Table 1.
Most target enzymes of serpins studied so far, if not all, are gen-
erally monomeric and/or have only one active site/enzyme mole-
cule, like trypsin, chymotrypsin, elastase, cathepsin G, cathepsins
B and L. Active caspases are obligate homodimers, with each
monomer composed of a large (p20) and a small (p10) subunit,
which are formed after the activation cleavage of the procaspase.
The large subunit p20 contains the catalytic cysteine and histidine.
Active caspases are therefore tetrameric structures resulting from
the association of two p20–p10 heterodimers in an anti-parallel
arrangement through the beta-sheet of the two p10 subunits and
each active protease comprises two active sites [18].
As shown in Fig. 1b, complete inhibition of caspase 8 and caspase
3 by bovSERPINA3-1 was achieved for an inhibitor concentration of
3.5 nM (I/E = 3.5 nM/7 nM = 0.5) (I/E ± S.D. for 5 independent deter-
minations: 0.53 ± 0.042) and 2 nM (I/E = 2 nM/2 nM = 1) (I/E ± S.D.
for 5 independent determinations: 1.13 ± 0.037), respectively. One
and two bovSERPINA3-1 molecules were therefore needed for total
inhibition of active tetrameric caspases 3 and 8, respectively.
With regard to bovSERPINA3-3 (Fig. 1c), the complete inhibition
of caspase 3 and caspase 8 was reached for an inhibitor concentra-
tion of 1 nM (I/E = 1 nM/2 nM = 0.5) (I/E ± S.D. for 5 independent
determinations: 0.50 ± 0.042) and 3.5 nM (I/E = 3.5 nM/7 nM =
0.5) (I/E ± S.D. for 5 independent determinations: 0.51 ± 0.043),
respectively. Hence, one bovSERPINA3-3 molecule is sufﬁcient to
inhibit totally either caspases.
To attest these ﬁndings we therefore look at the ability of these
serpins to form SDS-stable complexes with caspases.
3.2. SDS-stable inhibitors/caspases complexes
The suicide mechanism for inactivation of serpin target prote-
ases has been veriﬁed for a large set of monomeric enzyme like
trypsin, elastase and chymotrypsin [4]. Serpin inhibition of cys-Table 1
Stoechiometry (SI) for caspases inhibition by bovSERPINA3-1 and bovSERPINA3-3.
The values indicate the number of inhibitor molecule needed for inactivation of one
enzyme active site. Each value is the mean ± S.D. for ﬁve independent determinations.
bovSERPINA3-1 bovSERPINA3-3
Caspase 3 1.130 ± 0.037 0.500 ± 0.0.042
Caspase 8 0.530 ± 0.042 0.510 ± 0.0.043teine proteases, especially caspases, proceeds according to the
same trapping mechanism than for serine proteases [21]. Upon
SDS–PAGE, we could therefore expect to identify the covalent com-
plexes resulting from the covalent trapping of caspases by
bovSERPINA3s.
The bovSERPINA3/caspase complex formation was analysed by
Western blotting using the RabEndo 1A polyclonal antibody. In this
regard, bovSERPINA3-1 was more interesting since total inhibition
of caspases 3 and 8 is achieved for an I/E ratio of 2 and 1, respec-
tively. After preincubation of caspase 3 or 8 (5 nM) with bovSERP-
INA3-1 (molar ratio 1/2) at room temperature for 5 min, the
substrate (100 lM) was added and the mixture incubated for
10 min before heat denaturation (94 C, 4 min) of an aliquot in
the presence of SDS. As shown in Fig. 2, treatment of caspases 3
and 8 by bovSERPINA3-1 leads to a SDS-stable complex of about
100–110 kDa. According to the Mr value, the complexes would
comprise the cleaved inhibitor (70 kDa) and the covalently bound
caspase (30 kDa) transported to the distal pole of the serpin.
Stoechiometry studies showed that total inhibition of caspase 3
by bovSERPINA3-1 needs the binding of two serpin molecules, one
molecule per active site. The mechanism leading to a complex of
100–110 kDa (cleaved serpin + heterodimeric moiety of caspase
3) is probably similar to that reported for CrmA [9]. According to
these authors, enzyme trapping by the serpin induced a dissocia-
tion of the tetrameric active caspase 3 to its two heterodimeric
moieties, possibly through an alteration of the p10–p10 interface
which stabilized the tetrameric complex.
For bovSERPINA3-1 interaction with caspase 8, binding of one
molecule of inhibitor to one of the two active sites of the protease
is sufﬁcient for total inactivation. The mechanism by which theFig. 2. SDS-stable complexes of caspases 3 and 8 treated with bovSERPINA3-1. In
vitro complex formation of caspases incubated with bovSERPINA3-1 (E/I ratio: 1/2)
was revealed by Western blot with the mEndo-Ab (dilution 1/500) [13]. Note the
presence of the serpin dimer (140 kDa), the monomer (70 kDa) and a complex (C) of
about 100–110 kDa in lanes ‘‘caspase 3” and ‘‘caspase 8”. In lane ‘‘control”, the
puriﬁed bovSERPINA3-1 was run alone.
Table 2
Association rate constants for the inhibition of caspases 3 and 8 by bovSERPINA3-1
and A3-3. Each value is the mean ± S.D. for ﬁve independent determinations. Details
of the method are given in the Supplementary data.
kass (M1 s1)
Caspase 3 Caspase 8
Muscular bovSERPINA3-1 (4.23 ± 3.0)  105 (1.40 ± 2.0)  106
Muscular bovSERPINA3-3 (1.55 ± 1.7)  105 (2.72 ± 1.9)  106
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however unclear. Two possible reasons can be put forward: (a)
the second active site is compressed to the core serpin and inacces-
sible or (b) an important distortion of the second site resulting
from the global distortion of the tetrameric enzyme renders it un-
able to bind substrates. The 100–110 kDa complex observed upon
SDS–PAGE results probably from the dissociation of the terameric
caspase into its moieties during the heat denaturation process in
the presence of SDS.
Interestingly, a similar E/I inhibition ratio was noted for bov-
SERPINA3-3 interaction with both caspase 3 and 8, suggesting a
similar mechanism with the ﬁnal detection of a 100–110 kDa com-
plex upon SDS–PAGE. It is however evident that the behavior of the
caspase terameric structure upon interaction with bovSERPINA3s
might differ from that reported for CrmA and calls for further clar-
iﬁcation and detailed investigations.
3.3. Association rate constants
Besides the SI, another important parameter is the association
rate constant (kass) characterizing the inhibition of caspases 3
and 8 by bovSERPINA3-1 and A3-3 which was determined by the
progress curve method. The rate of substrate hydrolysis in the ab-
sence (Vo) and in the presence (Vi) of inhibitor was monitored con-
tinuously (Fig. 3). Values of Vi and Vo were used for the
determination of the equilibrium constant Ki [16]. On the other
hand and as illustrated in detail with an example in the Supple-
mentary data, the ﬂuorescence values obtained in the presence of
inhibitor were then used to calculate Ln ([P](t + dt)  [P]t) and the
results plotted versus time. From this plot, we deduced kobs values
(slope value) for each inhibitor concentration tested. The plot of
kobs versus inhibitor concentrations gave a straight line from which
kass can be derived from the slope which is equal to kass/(1 + S/Km)
[16]. For caspase 8, we always take care that the incubation length
was lower than 1000 s since after 1200 s the enzyme hydrolytic
activity tends to decrease.
According to the kass values depicted in Table 2 and ranging be-
tween 1.55  105 and 2.72  106 M1 s1, bovSERPINA3-1 and A3-Fig. 3. Progress curve analysis of the inhibition of caspases 3 and 8 by bovSERP-
INA3-1. Enzymes were added to assay buffer, containing 100 lM substrates, to a
ﬁnal concentration of 1 and 3.5 nM for caspases 3 and 8, respectively. After about
400 s for caspase 3 and 200 s for caspase 8 which is less stable, bovSERPINA3-1
(5 lL) was added and product formation was followed as a function of time. The
total volume of the reaction mixture was 500 lL. Abbreviations used: RF, relative
ﬂuorescence corresponding to the amount of product released; Vo, rate of substrate
hydrolysis in the absence of inhibitor; Vi, rate of substrate hydrolysis in the
presence of inhibitor; arrows indicate the time at which the inhibitor was added.3 are, undoubtedly, strong inhibitors of caspases 3 and 8. The bio-
logical signiﬁcance of these in vitro ﬁndings calls however for fur-
ther in situ investigations.
3.4. Potential scissile bonds within the bovSERPINA3s RCL
The length of the RCL, directly related to the inhibition mecha-
nism, is essential for the serpin to efﬁciently inhibit their target
protease. Although there are few documented exceptions, the
length up to the scissile bond was almost always 17 residues which
reduced extensively the potential P1 residue identity for inhibition
of their target protease [4]. According to the RCL sequences of bov-
SERPINA3-1 and A3-3 aligned in Fig. 4a, it has been established
that trypsin cleaved the serpin after Arg16 residue [6].
With regard to caspases 3 and 8, the question arising is what are
their P1 target residues? The term caspase is an acronym of cys-
teinyl-aspartate-cleaving protease in reference with their strict
cleavage speciﬁcity after Asp residues. Within the carboxy-termi-
nal RCL sequences of bovSERPINA3-1 and A3-3 (Fig. 4a), there is
only one Asp residue located at position 37 from the beginning
of the loop. To fulﬁll the above rule, the scissile bond would be lo-
cated around the 17th residue. In that case, it should be accepted
that caspases can cleave after other residues than Asp, a property
that has never been demonstrated.
Preliminary analysis of the N-terminal sequence of the C-termi-
nal peptide generated after the acyl-enzyme formation provided
N-terminal sequences for that peptide suggesting that the scissile
bond is Asp37-Thr38 (N-terminal peptide sequences for both casp-
ases: TQSIIFL. . .). To test this assumption, Asp37 residue of recom-
binant bovSERPINA3-3 was substituted to Ala37 by site-directed
mutagenesis and the activity of both mutated (M-D37/A37) and
wild-type (WT) proteins was tested against both trypsin and cas-
pase 3. According to Fig. 5A1, trypsin is similarly inhibited by the
recombinant WT and the M-D37/A37 bovSERPINA3-3. As expected,
both WT (Fig. 5B1, lane 2) and M-D37/A37 bovSERPINA3-3
(Fig. 5B1, lane 4) formed a SDS-stable complex with trypsin. In
addition, the association rates with trypsin are similar for both re-
combinant WT and mutated bovSERPINA3-3 (Table 3). Moreover
these association rate constants are comparable to that obtained
for the puriﬁed muscular bovSERPINA3-3 (Table 3).
By contrast, no inhibition of caspase 3 was observed with the
recombinant M-D37/A37 bovSERPINA3-3 as compared to the
wild-type protein (Fig. 5A2). It is worthy to note that the associa-
tion rate of the recombinant WT bovSERPINA3-3
(9.04  105 M1 s1) is similar to the value obtained with the puri-
ﬁed serpin (1.55  105 M1 s1). Moreover, while the WT bovSERP-
INA3-3 formed a SDS-stable complex with caspase 3 (Fig. 5B2, lane
2), the mutated form which lost its ability to inhibit caspase 3 was
also unable to form a SDS-stable complex with this protease
(Fig. 5B2, lane 4). Taken together, these results strongly suggested
that Asp37 is the P1 residue targeted by caspases 3 and 8.
The present ﬁndings are in total contradiction with the RCL
length invariance of serpins established with various monomeric
targeted serine proteases. Caspases are cysteine proteases and
whether the rule can be different for serpin interaction with
cysteine proteases is questionable. From what we actually know,
Fig. 4. Alignment of RCL sequences of members of the bovSERPINA3s family. (a) RCL sequence of bovSERPINA3-1 and A3-3 used throughout this study. (b) RCL sequence of
the other endopin 1 related bovSERPINA3s. (c) RCL sequence of the endopin 2 related bovSERPINA3-7 and A3-8. Residue in white bold on black background indicate P1
residues for trypsin (Arg16) and putative P1 residue for caspases 3 and 8 (Asp37 for A3-1 to A3-6; Glu39 and Asp39 for A3-7 and A3-8).
Fig. 5. (A) Capacities of recombinant WT and Asp37/Ala37 bovSERPINA3-3 mutant to inhibit trypsin (A1) and caspase 3 (A2). (B) BovSERPINA3-3 complexes with trypsin (B1)
and caspase 3 (B2). (B1) Western blot analysis of a mixture of trypsin (T) incubated with either WT bovSERPINA3-3 [W (lane 2) + T] and Asp37/Ala37 mutated bovSERPINA3-3
[M (lane 4) + T] (inhibitor/protease ratio: 10/1) as compared to the control samples [W (lane 1) or M (lane 3)  T] where the enzyme was omitted. Both Wild and mutated
isoforms exhibited a complex with trypsin (open arrow head). (B2) Western blot analysis of a mixture of human caspase 3 (C) incubated with either WT bovSERPINA3-3 [W
(lane 2) + C] and Asp37/Ala37 mutated bovSERPINA3-3 [M (lane 4) + C] (inhibitor/protease ratio: 10/1) as compared to the control samples [W (lane 1) or M (lane 3)  C] where
the enzyme was omitted. Whereas a SDS-stable complex of caspase 3 with the wild serpin (lane 2) was observed, no complex was detected with the mutated serpin (lane 4)
which lost its ability to inhibit caspase 3 (A2). All westerns were revealed with mEndo-Ab antibody. Abbreviations used: WT, wild-type bovSERPINA3-3; Asp37/Ala37 mutated
bovSERPINA3-3; W, wild serpin; M, mutated serpin; T, trypsin; C, caspase 3.
Table 3
Association rate constants of recombinant wild-type (WT) and Asp37/Ala37 mutated
bovSERPINA3-3 with trypsin and human recombinant caspase 3. Comparison with
association rate obtained with the bovSERPINA3-3 puriﬁed from bovine muscle
(muscular bovSERPINA3-3).
kass (M1 s1)
Trypsin Caspase 3
Muscular bovSERPINA3-3 0.67  106 1.55  105
Recombinant WT bovSERPINA3-3 1.87  106 9.04  105
Recombinant Asp37/Ala37 bovSERPINA3-3 0.78  106 No inhibition
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than Asp. Hence, no other cleavage site can be found in the RCL se-
quences of bovSERPINA3-1 and A3-3 suggesting that the cleaved
bond is Asp37-Thr38. However, clariﬁcation of this unusual ﬁndingcalls for more detailed investigations and, hopefully, for future X-
ray analysis of the tertiary structure of the free serpin and of the
complex with caspases.
3.5. RCL similarities of bovSERPINA3s
According to recent ﬁndings, bovSERPINA3-1 and A3-3 are
members of a family comprising at least eight genes located within
the same cluster at bovine chromosome 21q24 and encoding clo-
sely related serpins [12]. Hopping to identify other members of
bovSEPINA3 family potentially able to inhibit trypsin and/or casp-
ases, the C-terminal RCL sequences of the all members of this fam-
ily were aligned and compared (Fig. 4a–c).
From the comparative analysis of the mature proteins se-
quences, two subgroups can be distinguished within the bovSERP-
INA3s family, on the basis of their homology with endopins 1 and
2748 C.H. Herrera-Mendez et al. / FEBS Letters 583 (2009) 2743–27482. The ﬁrst one comprising bovSERPINA3-1 to A3-6 showed highest
homology with endopin 1-like serpins whereas the second encom-
passing bovSERPINA3-7 and A3-8 exhibited a greater homology
with Endopin 2-like serpins (Endopins 2A/2B/2C) [6,22,23]. Within
their RCL sequences, bovSERPINA3-1 to A3-6 exhibited an Arg res-
idue at position 16 and an Asp residue at position 37 (Fig. 4a and
b). All these serpins would therefore inhibit caspases and trypsin.
The two last members of this cluster, bovSERPINA3-7 and bov-
SERPINA3-8, very divergent in the C-terminal sequences, have no
Arg residue in the region of concern and will not inhibit trypsin,
an assumption agreeing well with the conclusion of Hwang and
collaborators [22] emphasizing that Endopin 2, corresponding to
bovSERPINA3-7, did not inhibit trypsin.
In bovSERPINA3-8 and A-3-7, an Asp residue and a Glu residue,
respectively, were noticed at position 39 (Fig. 4c). While we could
expect that bovSERPINA3-8 might be able to inactivate efﬁciently
caspases (Asp at position 39) but not trypsin, bovSERPINA3-7 will
probably be unable to inhibit caspases and, if some inhibition could
be detected, the inhibitory activity will be no more efﬁcient than
PI9 a serpin exhibiting a Glu residue at P1 position and considered
as a poor inhibitor of caspases as compared to the cowpox CrmA
which has an Asp residue at the P1 position [10].
In conclusion, the present work identiﬁed two serpins able to
inhibit strongly initiator and effector caspases and to form SDS-sta-
ble complexes with both groups of caspases, a feature never ob-
served with CrmA [9]. The mechanisms involved might be
different from those reported for CrmA but have in common the
trapping of the enzyme by the serpins. These serpins are widely
distributed in mammalian tissue and cells and belong to a family
presenting a surprising degree of compensation and redundancy
which can be compared to that often emphasized concerning the
caspase family [18]. This will obviously complicate the assessment
of their respective biological role in living tissues and cells. Another
question arising is the biological signiﬁcance of the existence of
two subgroups within the bovSERPINA3 family comparable to
the two major subgroups of caspases, i.e. the inﬂammatory and
the apoptotic subfamilies. Such assumption is supported by the
fact that members of the second subgroup, i.e. bovSERPINA3-7
and A3-8, are unable to inhibit trypsin but are strong inhibitor of
elastase [23], a protease playing a central role in inﬂammatory pro-
cesses [24].
Besides highly specialized and restricted functions in living cells
[25], for this group of SERPINA3-like, future investigations must be
preferably focused on a more general role in processes common to
all mammalian tissues and cells, and, in this context, apoptosis and
inﬂammatory processes are probably the ﬁrst to be considered.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2009.07.055.
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